Hikma Pharmaceuticals PLC stock (GB00B128J450): Active in growing psychedelics and iron drugs markets

Hikma Pharmaceuticals PLC, a global developer and supplier of essential medicines, continues to demonstrate strength in niche pharmaceutical segments. Recent market reports highlight its 11.3% share in the psychedelic drugs market, driven by expertise in CNS pharmaceuticals and injectable therapies, according to openPR as of May 2026. Separately, the IV and oral iron drugs market, where Hikma participates, was valued at USD 8.65 billion in 2025 and is forecast to grow to USD 22.86 billion by 2034, per Straits Research as of 2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Hikma Pharmaceuticals PLC: core business model

Hikma Pharmaceuticals PLC develops, manufactures, and supplies a broad portfolio of generic, specialty, and branded pharmaceutical products. The company offers over 820 high-quality medicines as of February 2026, targeting essential healthcare needs worldwide, according to MarketBeat as of 2026. Its operations span injectables, oral solids, and other dosage forms, with a strong emphasis on affordability and reliability.

Headquartered in the UK, Hikma maintains manufacturing facilities in key regions including the US, Europe, and the Middle East. This global footprint supports its role as a trusted partner for healthcare providers, particularly in underserved markets. For US investors, Hikma's presence in Berkeley Heights, NJ, underscores its exposure to the lucrative American pharmaceutical sector, as noted in recent job postings on Indeed as of 2026.

Main revenue and product drivers for Hikma Pharmaceuticals PLC

Hikma derives revenue primarily from its generic and injectable portfolios, which address high-volume therapeutic areas like cardiology, oncology, and pain management. The company's specialty products, including those in CNS categories, contribute to growth in emerging markets such as psychedelics. Its 11.3% market share in psychedelics is supported by manufacturing capabilities, positioning it for expansion as demand rises, per the openPR report.

In the iron drugs space, Hikma benefits from market growth projections from USD 9.62 billion in 2026 to USD 22.86 billion by 2034. These segments align with global health trends, including anemia treatment and mental health innovations, providing diversified revenue streams for the company.

Industry trends and competitive position

The pharmaceuticals industry is witnessing rapid growth in niche areas like psychedelic therapies and iron supplementation, driven by regulatory advancements and rising prevalence of related conditions. Hikma competes with players like Amgen, Novartis, and Cipla in segments such as sertraline and iron drugs, as listed in market analyses from Market Research Intellect as of 2026. Its expertise in injectables gives it an edge in hospital-supplied markets.

Hikma's inclusion in indices like the EN Developed Europe Total Market NR highlights its stable position among European-listed firms, according to Euronext as of 2026. This visibility appeals to US investors seeking international diversification with US market ties.

Why Hikma Pharmaceuticals PLC matters for US investors

Hikma's US operations, including facilities in New Jersey, provide direct exposure to the world's largest pharma market. Its generic offerings help control healthcare costs, aligning with US policy priorities. Investors tracking London-listed stocks (LSE: HIK) can access Hikma via ADRs or international brokers, benefiting from its role in essential medicines amid ongoing supply chain demands.

Conclusion

Hikma Pharmaceuticals PLC maintains a solid position in generics and emerging pharma niches like psychedelics and iron drugs, with recent market reports underscoring its competitive shares and growth potential. US investors may note its American footprint and index inclusion as points of relevance. The company's broad portfolio supports resilience across global markets, though sector dynamics remain key to monitor.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.